ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 11.2% in April

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 8,110,000 shares, an increase of 11.2% from the March 31st total of 7,290,000 shares. Based on an average trading volume of 2,530,000 shares, the days-to-cover ratio is presently 3.2 days.

Analysts Set New Price Targets

ADMA has been the topic of several analyst reports. Cantor Fitzgerald lifted their price target on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Mizuho boosted their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $7.88.

ADMA Biologics Trading Up 1.7 %

NASDAQ ADMA opened at $6.55 on Monday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16. The company has a 50-day simple moving average of $6.07 and a 200-day simple moving average of $4.89. The firm has a market capitalization of $1.49 billion, a PE ratio of -50.38 and a beta of 0.46. ADMA Biologics has a one year low of $3.06 and a one year high of $6.76.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The business had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. On average, equities analysts forecast that ADMA Biologics will post 0.3 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Steve Elms sold 407,000 shares of the firm’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total value of $2,527,470.00. Following the transaction, the director now owns 3,208,671 shares of the company’s stock, valued at approximately $19,925,846.91. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is owned by insiders.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP raised its holdings in shares of ADMA Biologics by 87.7% in the 3rd quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock worth $867,000 after purchasing an additional 113,184 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of ADMA Biologics by 22.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after acquiring an additional 224,696 shares during the period. American Century Companies Inc. raised its holdings in shares of ADMA Biologics by 20.8% during the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after acquiring an additional 840,761 shares during the period. Aigen Investment Management LP acquired a new stake in shares of ADMA Biologics during the third quarter valued at approximately $140,000. Finally, SG Americas Securities LLC raised its holdings in shares of ADMA Biologics by 417.3% during the fourth quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 75,213 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.